What the scores actually show at three years

Three years after treatment, patients in the Jerosch et al. prospective Post-Market Clinical Follow-up (PMCF) study had gained a mean of 32.4 points on the IKDC Subjective Knee Score, reaching a mean of 80.1 out of 100. A score in that region corresponds to a knee that functions well for most daily and recreational activities — patients at this level can typically walk, climb stairs, and return to moderate sport without significant restriction.

That gain is clinically meaningful in a precise sense: the established Minimal Clinically Important Difference (MCID) for the IKDC is 16.7 points, and the Jerosch result more than doubles it. Across the four knee studies reviewed in the manufacturer's April 2025 Clinical Evaluation Report (CER), every study exceeded this threshold — making a roughly 30-point improvement a consistent finding across the evidence base rather than an isolated result.

On MRI, repair tissue quality is assessed using the MOCART score, a seven-variable system that rates how completely the defect has been filled and how well the new tissue integrates with the surrounding native cartilage. In European ChondroFiller® knee studies, MOCART scores stabilised in the 81.6–84.3 range at one year — consistent with greater than 80% defect filling and sound border integration. Available three-year data align with this band rather than showing decline, suggesting that structural repair holds once established.

Published five-year data specific to ChondroFiller® have not yet appeared in the peer-reviewed literature; that evidence gap and its implications are examined in detail later in this article.

What IKDC and MOCART actually measure

Think of these two tools as a pair of report cards — one completed by the patient, one by the MRI scanner.

The IKDC Subjective Knee Score is an 18-question patient questionnaire covering symptoms, daily activities, and sport. Each answer is weighted and the total converted to a 0–100 scale, where 100 represents a fully functioning knee. Because it captures what the patient actually experiences — pain climbing stairs, confidence on uneven ground, ability to run — it is the primary measure of whether treatment has made a meaningful difference. The threshold for a change that patients notice in everyday life (the Minimal Clinically Important Difference, or MCID) sits at 16.7 points.

The MOCART 2.0 score (Schreiner et al., 2019) is the MRI counterpart. Seven variables assess how completely the treated defect has been filled, how smoothly the repair tissue blends with the surrounding native cartilage, and how well the borders between old and new tissue have closed. It also runs from 0 to 100; scores above 80 indicate good structural repair, but the cartilage literature flags incomplete border integration — which can appear as a bright line on MRI at late follow-up — as a potential sign of long-term vulnerability even when the overall score looks reassuring.

The two measures are complementary: a patient can feel well whilst the MRI reveals incomplete integration, or vice versa, which is why both matter when judging long-term durability.

How scores change from injection to three years

The improvement after a ChondroFiller® injection does not arrive all at once.

Four weeks post-injection, mean MOCART scores in the key ChondroFiller® knee study stood at 65.3 — reflecting early, partial scaffold colonisation rather than completed repair. Cell migration has begun, but newly recruited progenitor cells have not yet laid down sufficient matrix to fill the defect or integrate with the surrounding native cartilage.

By twelve months, the picture had changed substantially: MOCART reached 81.6, a 16-point structural gain driven by progressive cell recruitment and repair-tissue organisation. Functional improvement follows a similar arc — IKDC scores in knee cartilage studies tend to accelerate between months three and twelve as maturing repair tissue becomes progressively better at bearing load.

The critical question is what happens after that. In the Jerosch et al. PMCF cohort, three-year scores were sustained and in several patients marginally higher than at twelve months — indicating a trajectory of continued stability rather than early gain followed by gradual decline.

The biological explanation matters for patient counselling. ChondroFiller® is an acellular scaffold: it contains no pre-loaded cells. The patient's own progenitor cells migrate in from the synovium and subchondral bone, and that process continues for months after the injection. Early MRI results therefore understate the eventual structural outcome. A three-month scan represents an intermediate snapshot; twelve months is a more informative assessment point. Patients who feel progress is slow in the first few months can be reassured that deliberate, biology-paced maturation is the expected mechanism of acellular matrix-induced chondrogenesis — not a sign that treatment has not worked.

Evidence gaps and what they mean for decision-making

Three gaps in the current evidence base are worth naming clearly.

The five-year horizon. No peer-reviewed data specific to ChondroFiller® extend beyond three years. The Jerosch et al. PMCF study is the longest published follow-up, and it demonstrates sustained improvement at that point — but what happens between years three and five remains formally uncharacterised for this product. The broader cartilage repair literature includes five-year series for MACI and microfracture, but those involve different patient populations and delivery mechanisms, so direct comparison with ChondroFiller's three-year profile is not available in the published record.

Sponsorship context. Every pivotal figure derives from investigations captured in the manufacturer's Clinical Evaluation Report (CER, Meidrix Biomedicals GmbH, April 2025). This is standard practice for CE-marked Class III devices but introduces a recognised risk of sponsorship bias that should sit alongside the headline numbers when readers are weighing confidence levels.

Independent replication. London Cartilage Clinic has stated that its own real-world outcome data are in preparation for publication. Until that work appears, the 32.4-point IKDC gain and 81–84 MOCART range reported in the CER have not been independently replicated in the peer-reviewed literature.

Procedural safety is the one dimension where the evidence position is more settled: an approximately 0% complication rate and a 3–8% reoperation rate across more than 19,000 cases globally constitute a robust real-world signal, and this record is consistent across the published literature.

Which patients tend to get the best results

The three-year outcomes described above apply to a specific patient profile — identifying it matters as much as understanding the headline numbers.

ChondroFiller® is designed for focal articular cartilage defects: discrete areas of cartilage loss surrounded by structurally sound native tissue. The scaffold's cell-recruitment mechanism depends on that surrounding tissue. Where adjacent cartilage is itself degraded, or where disease is diffuse across the joint, the biological colonisation process is compromised from the outset. Bone-on-bone presentations and advanced diffuse osteoarthritis fall outside the indication.

Several other factors influence individual response. Defect size and location affect how fully the scaffold is colonised. Body mass index, alignment, and activity level shape the mechanical environment in which repair tissue matures. Inflammatory arthritis can alter the joint's cellular milieu in ways that blunt the effectiveness of acellular matrix-induced chondrogenesis.

The Jerosch et al. cohort reflects joint-preservation cases: patients with focal lesions, reasonable surrounding cartilage, and sufficient biological capacity for endogenous repair. Whether a given defect matches that profile is a clinical question — one that requires MRI characterisation and, where relevant, biomechanical evaluation of loading mechanics. A Lincolnshire Knee assessment can include detailed cartilage imaging to inform that evaluation; suitability ultimately rests on objective structural findings, not on symptoms alone.

Getting assessed at Lincolnshire Knee

For patients in Lincolnshire and the surrounding region, a consultant assessment at Lincolnshire Knee requires no GP referral and no NHS waiting list. Clinics are based in Sleaford NG34 — which houses an Open MRI suite and a dedicated Regeneration Hub — and Grantham NG31, offering consultation and diagnostics.

At that assessment, a consultant will review the cartilage defect profile, joint condition, and clinical history to determine whether the injectable scaffold pathway is appropriate, whether an alternative injection option such as PRP is better suited, or whether a surgical referral is the right next step.

Lincolnshire Knee accepts patients without referral. Book an assessment at lincolnshireknee.co.uk.